[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 168
51. Sheng XH, Gao CF, Ji XQ, Wei D, Zheng GB: [Comparative study of recurrent colon cancer and recurrent rectal cancer after radical resection]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Jun;13(6):409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study of recurrent colon cancer and recurrent rectal cancer after radical resection].
  • OBJECTIVE: To explore the difference in tumor biological behaviors and prognosis between recurrent colon cancer and recurrent rectal cancer after radical operation.
  • METHODS: Complete clinical and follow-up data of 132 patients with colorectal cancer developed recurrence,including 36 colon cancers and 96 rectal cancers, after curative resection were retrospectively analyzed and compared with respect of clinical pathological features and prognosis between colon and rectal cancer.
  • RESULTS: Significant differences were found in primary tumor gross type, histological type, tumor differentiation and lymph node metastasis between colon and rectal cancer(P<0.05).
  • Colon cancer recurred earlier than rectal cancer after radical surgery with the median time to recurrence being 14.0 months and 21.5 months, respectively(P=0.028).
  • The difference in multiple sites recurrence was also found between colon(n=16, 44.4%) and rectal cancer(n=65, 67.7%)(P=0.014).
  • The 3-year survival rate of recurrent rectal cancer was better than that of colon cancer (24.8% vs 15.6%, P=0.026).
  • CONCLUSION: There are some differences in tumor biological behaviors between colon and rectal cancer, and the prognosis of rectal cancer with recurrence is better than that of colon cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20577916.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


52. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum; 2008 Jun;51(6):829-35; discussion 835-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience.
  • PURPOSE: This study was designed to determine whether high-resolution anoscopy and targeted surgical destruction of anal high-grade squamous intraepithelial lesions is effective in controlling high-grade squamous intraepithelial lesions while preserving normal tissues.
  • Recurrent high-grade squamous intraepithelial lesions occurred in 114 patients (57 percent) at an average 19 (range, 3-92) months; 26 of these required surgery.
  • Despite treatment, three patients progressed to invasive cancer (1.2 percent).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Proctoscopy

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363070.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Pizzocaro G, Algaba F, Horenblas S, Solsona E, Tana S, Van Der Poel H, Watkin NA, European Association of Urology (EAU) Guidelines Group on Penile Cancer: EAU penile cancer guidelines 2009. Eur Urol; 2010 Jun;57(6):1002-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EAU penile cancer guidelines 2009.
  • CONTEXT: Squamous cell carcinoma (SCC) of the penis is a relatively rare but ominous disease.
  • Similarities in etiology with SCC of the head and neck, the female genitalia, and the anal canal have been found.
  • Adjuvant and neoadjuvant chemotherapy showed promising results in patients with advanced or recurrent disease.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Penile Neoplasms / diagnosis. Penile Neoplasms / therapy. Quality of Life / psychology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20163910.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Switzerland
  •  go-up   go-down


5
Advertisement
4. Ozturk M, Kordan Y, Cangul H, Dogan HS, Kilicarslan H, Vuruskan H, Oktay B: Association of urokinase gene 3'-UTR T/C polymorphism with calcium oxalate urolithiasis in children. Int Urol Nephrol; 2008;40(3):563-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urokinase concentrations are lower and urokinase gene 3'-UTR T/C polymorphism is higher in patients with recurrent stones.
  • Our aim was to investigate the role of urokinase gene 3'-UTR T/C polymorphism in childhood recurrent stone disease.
  • MATERIAL AND METHODS: A control group of 40 healthy children having no history of stone formation (group 1) (mean age 10.5+/-4.2 years), 40 children (mean age 10.5+/-4.33 years) who had calcium oxalate stones for the first time (group 2), and 40 patients (mean age 11.2+/-3.8 years) with recurrent calcium oxalate stone disease (group 3) were included in the study.
  • CONCLUSIONS: Urokinase 3'-UTR T/C gene polymorphism seems to appear more commonly in children with recurrent calcium oxalate stone disease than in healthy children and in those with stones for the first time.
  • These results suggest that the urokinase gene might play a role in childhood recurrent calcium oxalate stone disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Hypotheses. 1997 Jul;49(1):57-9 [9247909.001]
  • [Cites] J Biol Chem. 1989 Feb 15;264(5):2846-52 [2492525.001]
  • [Cites] Urol Res. 1992;20(1):41-4 [1531276.001]
  • [Cites] J Exp Med. 1997 Mar 3;185(5):963-8 [9120402.001]
  • [Cites] Histochem Cell Biol. 1996 Jan;105(1):53-60 [8824906.001]
  • [Cites] Cell. 1993 Jan 15;72(1):19-28 [8380757.001]
  • [Cites] Kidney Int. 1996 Nov;50(5):1706-12 [8914040.001]
  • [Cites] Urol Int. 2006;77(1):81-4 [16825821.001]
  • [Cites] Urol Res. 1995;23(5):335-8 [8839391.001]
  • [Cites] Ann Intern Med. 1989 Dec 15;111(12):1006-9 [2688503.001]
  • [Cites] Nature. 1999 Oct 21;401(6755):734 [10548090.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1141-52 [1528210.001]
  • [Cites] BJU Int. 2001 Sep;88(4):432-6 [11564035.001]
  • [Cites] Urology. 2002 Mar;59(3):458-61 [11880102.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jul;82(13):4448-52 [2989821.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Dec;20(4):569-72 [11876553.001]
  • [Cites] Med Hypotheses. 1991 Dec;36(4):368-70 [1809856.001]
  • [Cites] BJU Int. 2001 Feb;87(3):168-71 [11167636.001]
  • [Cites] J Endourol. 2006 Feb;20(2):157-60 [16509805.001]
  • [Cites] Urol Res. 2001 Apr;29(2):94-7 [11396735.001]
  • [Cites] Thromb Haemost. 1997 Mar;77(3):434-5 [9065988.001]
  • [Cites] J Clin Lab Anal. 2004;18(5):276-9 [15356878.001]
  • (PMID = 18240004.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 2612HC57YE / Calcium Oxalate; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


55. Roncucci L: Local recurrences of rectal cancer. Minerva Chir; 2005 Jun;60(3):167-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrences of rectal cancer.
  • Data from cancer registries show that incidence of rectal cancer is still high in Italy, while mortality rates are slightly decreasing in most recent years.
  • The rectum may be defined as the tract of the large bowel distal to 12 cm from the anal verge.
  • Pelvic recurrence is evident as a regrowth of cancer in and around the tumor bed.
  • A wide range of recurrence rates after operation for rectal cancer are reported, spanning from 3% to over 30%.
  • This technique has decreased dramatically recurrence rates of rectal cancer, though increasing the risk of local complications.
  • Management of locally recurrent tumors is still unsatisfactory and surgery is feasible only in less than 10% of cases.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985992.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng; ita
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 80
  •  go-up   go-down


56. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY: Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest; 2009 Jun;27(5):549-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
  • To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology.
  • Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer.
  • Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1128-36 [16489065.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10911-8 [17108128.001]
  • [Cites] JAMA. 2006 May 17;295(19):2234-8 [16705097.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3973-8 [16921049.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2317-21 [17119066.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3215-31 [17158741.001]
  • [Cites] Eur Urol. 2007 Mar;51(3):665-74; discussion 674 [16956712.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5941-5 [11085508.001]
  • [Cites] J Urol. 2001 Jan;165(1):119-25 [11125379.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1815-26 [11696442.001]
  • [Cites] Urology. 2001 Jun;57(6):1033-7 [11377299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5 [11891299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3376-85 [12177097.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Urology. 2003 Feb;61(2):365-9 [12597949.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1174-8 [12800218.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1100-9 [12801870.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3877-82 [12873976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] J Pathol. 2004 Feb;202(2):233-40 [14743506.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1975-86 [15026333.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1633-8 [15073850.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 May 1;196(3):422-30 [15094313.001]
  • [Cites] Urologe A. 2004 May;43(5):573-9 [15029477.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3935-6 [15217922.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):125-35 [15247353.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Eur Urol. 2004 Nov;46(5):660-9; discussion 669 [15474280.001]
  • [Cites] J Mol Biol. 1987 Jul 20;196(2):261-82 [3656447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):549-53 [8621277.001]
  • [Cites] Anal Biochem. 1998 Sep 10;262(2):185-92 [9750131.001]
  • [Cites] Clin Chim Acta. 2004 Dec;350(1-2):181-8 [15530476.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):103-15 [15657340.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4037-43 [15930338.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6582-8 [16166436.001]
  • [Cites] J Urol. 2005 Dec;174(6):2191-6 [16280762.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8321-5 [16322291.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):37-50 [16485345.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):17-22 [17464242.001]
  • [Cites] J Urol. 2007 Aug;178(2):459-63; discussion 463 [17561132.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1679-86 [17601725.001]
  • [Cites] J Urol. 2008 Apr;179(4):1354-60; discussion 1360-1 [18289596.001]
  • [Cites] J Urol. 2008 Jun;179(6):2207-10; discussion 2210-1 [18423693.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):659-64 [18692327.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 2):S11-5 [17084157.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):715-7 [16705126.001]
  • (PMID = 19229700.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA091956-080012; United States / NCI NIH HHS / CA / P50 CA091956; United States / NCI NIH HHS / CA / CA091956; United States / NCI NIH HHS / CA / P50 CA091956-080012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS99244; NLM/ PMC2693083
  •  go-up   go-down


57. Huh JW, Park YA, Lee KY, Kim SA, Sohn SK: Recurrences after local excision for early rectal adenocarcinoma. Yonsei Med J; 2009 Oct 31;50(5):704-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The role of local excision in treating rectal cancer patients continues to be controversial.
  • The aim of this study was to evaluate the long-term oncological results of local excision for early rectal adenocarcinomas and review the outcomes of salvage therapy on rectal cancer patients.
  • The mean tumor distance from the anal verge was 5 cm (range, 1-10 cm).
  • Of the eight recurrent patients with surgical salvage, five survived with no evidence of disease at the time of this analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):875-9 [12130873.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):1075-90, x-xi [12507210.001]
  • [Cites] J Am Coll Surg. 2004 Sep;199(3):353-60 [15325603.001]
  • [Cites] Dis Colon Rectum. 1992 Feb;35(2):131-6 [1735314.001]
  • [Cites] Surgery. 1992 May;111(5):555-61 [1598675.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):388-92 [9106685.001]
  • [Cites] Am J Surg. 1998 May;175(5):360-3 [9600277.001]
  • [Cites] Jpn J Clin Oncol. 1998 Oct;28(10):621-5 [9839503.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):49-54 [10400036.001]
  • [Cites] Colorectal Dis. 2005 Jan;7(1):35-42 [15606582.001]
  • [Cites] Surg Oncol. 2004 Dec;13(4):223-34 [15615660.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):711-9; discussion 719-21 [15768186.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1169-75 [15793645.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1380-8 [15906120.001]
  • [Cites] Dis Colon Rectum. 2007 Apr;50(4):523-33 [17285233.001]
  • [Cites] J Comput Assist Tomogr. 2007 Jul-Aug;31(4):569-71 [17882033.001]
  • [Cites] Dis Colon Rectum. 2007 Oct;50(10):1520-5 [17674104.001]
  • [Cites] J Surg Res. 2008 Aug;148(2):244-50 [17936793.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):313-22 [10661337.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):345-51 [10714627.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30 [12368681.001]
  • (PMID = 19881976.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2768247
  • [Keywords] NOTNLM ; Recurrence / local excision / rectal adenocarcinoma
  •  go-up   go-down


58. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • For patients who present with persistent or locally recurrent disease, salvage abdominoperineal resection is the treatment of choice.
  • RESULTS: Eleven patients underwent radical salvage surgery for persistent disease and 20 patients for recurrent disease.
  • Twelve patients developed recurrent disease after radical salvage surgery.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Yu J, Zhang C, Wang YN, Hu YF, Cheng X, Li GX: [Laparoscopic versus open total mesorectal excision for the middle-lower rectal cancer: a clinical comparative study]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov;12(6):573-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic versus open total mesorectal excision for the middle-lower rectal cancer: a clinical comparative study].
  • OBJECTIVE: To evaluate the feasibility, safety, radicality and short-term outcome of laparoscopic total mesorectal excision(TME) in comparison with open procedure for the middle-lower rectal cancer.
  • METHODS: From November 2005 to October 2008, 93 patients with middle-lower rectal cancer received laparoscopic total mesorectal excision (LTME group), while 105 patients underwent conventional open TME (OTME group).
  • The anal sphincter preserved procedure accounted for 82.8% in LTME group and 81.9% in OTME group.
  • The recurrent rate and overall survival rate were 4.4% and 97.8% in LTME group, with no significant difference compared to those in OTME group (7.3% and 97.9%, P >0.05).
  • CONCLUSIONS: Laparoscopic TME for middle-low rectal cancer is safe and feasible, and can potentially offer all the benefits of a minimally invasive approach and achieve satisfactory oncological outcome,which may lead to a better future of the TME technique.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921566.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


60. Hamada M, Ozaki K, Iwata J, Nishioka Y, Horimi T: A case of rectosigmoid cancer metastasizing to a fistula in ano. Jpn J Clin Oncol; 2005 Nov;35(11):676-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rectosigmoid cancer metastasizing to a fistula in ano.
  • We herein report a case of rectosigmoid cancer metastasizing to a fistula in ano.
  • A 53-year-old man complaining of anal bleeding consulted another hospital.
  • He had been suffering from an anal fistula since 7 years.
  • On the left upper side of the skin surface around the anus a fistula end was seen as a hole that tunneled down into the back passage, although no hard tumor was palpable on the hole.
  • The post-operative pathological diagnosis was rectosigmoid cancer, Type 2, T2, N0, M0, stage II.
  • The anal fistula was a simple type and mucinous discharge was not observed.
  • On 23 February 2004, coring out the anal fistula was performed by the former hospital.
  • We diagnosed this tumor as metastatic adenocarcinoma from a rectosigmoid cancer.
  • Recurrent lesions were not seen during the first year after the first operation.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275674.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • 9 patients suffered from a recurrent tumour.
  • After a mean follow up of 44 months (r.: 18-84) 8 patients had deceased for recurrent disease, 15 were alive with a disease progression (2 pelvic recurrences and 13 pure distant deposits) and 24 were alive, without disease.
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


62. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, the hypothesis that ABCs are lesions reactive to local hemodynamics has been challenged after the discovery of specific recurrent chromosomal abnormalities.
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bevacizumab. Carcinoma / complications. Cell Transformation, Neoplastic / pathology. Diabetes Mellitus, Type 2 / complications. Embolization, Therapeutic. Female. Humans. Hyperplasia. In Situ Hybridization, Fluorescence. Kidney Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Thyroid Gland / pathology. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]
  • [Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]
  • [Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]
  • [Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]
  • [Cites] Surg Today. 1994;24(5):476-80 [8054822.001]
  • [Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]
  • [Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • (PMID = 19838726.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


63. Merg A, Wirtzfeld D, Wang J, Cheney R, Dunn KB, Rajput A: Viability of endoscopic and excisional treatment of early rectal carcinoids. J Gastrointest Surg; 2007 Jul;11(7):893-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rectal carcinoids were a mean 9.2 +/- 3.4 cm from the anal verge and a mean 9 +/- 6 mm in size.
  • No patient developed recurrent carcinoid disease for a 20-year overall survival of 70%.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Apr 1;79(7):1294-8 [9083149.001]
  • [Cites] Cancer. 1975 Mar;35(3):588-91 [1111928.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Int J Colorectal Dis. 1992 Feb;7(1):11-4 [1588217.001]
  • [Cites] Endoscopy. 1997 Mar;29(3):171-5 [9201465.001]
  • [Cites] Surg Today. 1997;27(2):112-9 [9017986.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1330-2 [15362745.001]
  • [Cites] Dis Colon Rectum. 1964 May-Jun;7:197-206 [14159370.001]
  • [Cites] Ann Surg. 1990 Jan;211(1):67-71 [2294847.001]
  • [Cites] Jpn J Surg. 1990 Jul;20(4):468-71 [2201813.001]
  • [Cites] Am J Gastroenterol. 1993 Nov;88(11):1949-53 [8237948.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):91-7 [11786770.001]
  • [Cites] Am J Pathol. 1928 May;4(3):181-212.19 [19969788.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):717-25 [1643994.001]
  • [Cites] Dis Colon Rectum. 1996 Jun;39(6):643-8 [8646950.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] Dis Colon Rectum. 1991 Jan;34(1):31-6 [1991417.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):135-40 [2293859.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] Cancer. 1971 Jul;28(1):175-80 [5110628.001]
  • [Cites] Surg Gynecol Obstet. 1981 Mar;152(3):268-72 [7466571.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):549-56 [10998653.001]
  • [Cites] World J Surg. 1998 Jun;22(6):628-33; discussion 634 [9597939.001]
  • [Cites] Surgery. 1983 Oct;94(4):670-6 [6623366.001]
  • [Cites] Am J Surg. 1990 Sep;160(3):262-5 [2393053.001]
  • (PMID = 17458590.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Tilney HS, Heriot AG, Trickett JP, Massouh H, Edwards DP, Mellor SG, Gudgeon AM: The use of intra-operative endo-anal ultrasound in perianal disease. Colorectal Dis; 2006 May;8(4):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of intra-operative endo-anal ultrasound in perianal disease.
  • Pathologies encountered were fistula-in-ano (42%), fissure-in-ano (26%), complicated perianal sepsis (16%) and carcinoma (5%).
  • In 22 cases (51.2%) the EAUS findings affected the surgical management (extent of muscle above a fistula 9 cases, extent of sphincterotomy 7 cases, site of sepsis identified 2 cases, exclusion of sepsis 2 cases, assessment of cancer resectability 1 case, biopsy of intersphincteric lesion 1 case).
  • While not essential, it is a useful adjunct especially in recurrent perianal sepsis, undiagnosed anorectal pain and anal fissure.
  • [MeSH-major] Anus Diseases / surgery. Anus Diseases / ultrasonography. Endosonography. Intraoperative Care. Rectal Fistula / surgery. Rectal Fistula / ultrasonography

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630240.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Sharma S, Sharma MC, Gupta DK, Sarkar C: Angiogenic patterns and their quantitation in high grade astrocytic tumors. J Neurooncol; 2006 Aug;79(1):19-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Limited follow up data showed all recurrent grade IV tumors to be of glomeruloid type.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1998 Apr;29(4):352-8 [9563784.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1216-21 [15026804.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Clin Neurosurg. 1976;23:440-53 [975695.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Acta Neuropathol. 1989;77(4):369-78 [2469286.001]
  • [Cites] Histopathology. 2001 Oct;39(4):402-8 [11683942.001]
  • [Cites] Brain Pathol. 1994 Jul;4(3):207-18 [7524960.001]
  • [Cites] Ai Zheng. 2005 Jan;24(1):19-22 [15642194.001]
  • [Cites] Lung Cancer. 2003 Mar;39(3):289-96 [12609567.001]
  • [Cites] Anal Cell Pathol. 1992 Nov;4(6):409-19 [1457384.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):75-85 [8699229.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):675-7 [15491962.001]
  • [Cites] J Pathol. 1992 Nov;168(3):257-62 [1281874.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):477-82 [10470824.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):513-20 [9488306.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):487-93 [2552044.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):134-41 [10393366.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] Tumori. 2001 Jan-Feb;87(1):47-53 [11669558.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):46-52 [15850004.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):165-72 [11245275.001]
  • [Cites] J Clin Pathol. 2002 Jul;55(7):530-4 [12101201.001]
  • [Cites] Leukemia. 2003 Jan;17(1):89-97 [12529665.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):239-47 [14586069.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):57-66 [11849564.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):516-26 [14595708.001]
  • [Cites] Biochem J. 1994 Nov 1;303 ( Pt 3):681-95 [7980433.001]
  • [Cites] Histopathology. 2003 Apr;42(4):395-402 [12653952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193-207 [8380567.001]
  • [Cites] J Neurooncol. 1997 May;32(3):253-65 [9049887.001]
  • [Cites] Clin Exp Dermatol. 2003 May;28(3):310-4 [12780721.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):426-9 [15043465.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] J Neurosurg. 1994 Dec;81(6):902-9 [7525899.001]
  • [Cites] Adv Pharmacol. 1990;21:149-83 [2176094.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1369-76 [11516097.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Histopathology. 2005 May;46(5):481-9 [15842629.001]
  • [Cites] Acta Neuropathol. 2000 Jul;100(1):101-5 [10912927.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):133-43 [12744467.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2941-55 [15126324.001]
  • [Cites] Acta Neuropathol. 1993;85(5):508-14 [7684179.001]
  • (PMID = 16807783.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol; 2005 Sep 1;23(25):6199-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study.
  • Also, hospital treatment was recorded for diseases possibly related to late side effects of rectal cancer treatment.
  • PATIENTS AND METHODS: Long-term morbidity was assessed in patients from the prospective randomized TME trial, which investigated the efficacy of 5 x 5 Gy before TME surgery for mobile rectal cancer.
  • Dutch patients without recurrent disease were sent a questionnaire.
  • However, irradiated patients, compared with nonirradiated patients, reported increased rates of fecal incontinence (62% v 38%, respectively; P < .001), pad wearing as a result of incontinence (56% v 33%, respectively; P < .001), anal blood loss (11% v 3%, respectively; P = .004), and mucus loss (27% v 15%, respectively; P = .005).
  • CONCLUSION: Although preoperative short-term radiotherapy for rectal cancer results in increased local control, there is more long-term bowel dysfunction in irradiated patients than in patients who undergo TME alone.
  • Rectal cancer patients should be informed on late morbidity of both radiotherapy and TME.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135487.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J, Pan QJ: ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol; 2010 Feb;32(1):45-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study.
  • OBJECTIVE: To determine whether ImmunoCyt (uCyt+) immunofluorescence and cytokeratin 20 (CK20) immunocytochemistry add additional diagnostic value in the detection of urothelial carcinoma (UC) in samples of urine liquid-based cytology (LBC).
  • RESULTS: Of 169 inpatients, 135 cases had histologic diagnoses, including 93 cases of UC with primary tumors in 68 and recurrent tumors in 25, 26 cases of other urologic malignancies and 16 cases of benign urologic lesions.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701087.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


68. Gazdar AF, Gao B, Minna JD: Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer; 2010 Jun;68(3):309-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?
  • Perhaps the most important finding is that every important, recurrent genetic and epigenetic change including gene mutations, deletions, amplifications, translocations and methylation-induced gene silencing found in tumors has been identified in cell lines and vice versa.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Oncogene. 2009 Aug;28 Suppl 1:S24-31 [19680293.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):1018-20 [19692681.001]
  • [Cites] PLoS One. 2009;4(10):e7464 [19826477.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1537-47 [10793065.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3200-5 [11306509.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):315-9 [12001993.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4577-86 [12085236.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Cancer Biol Ther. 2002 Jan-Feb;1(1):65-9 [12170765.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8510-4 [12466971.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2840-5 [15087401.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3060-71 [15126342.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):57-9 [15325095.001]
  • [Cites] Oncogene. 2004 Sep 16;23(42):7047-52 [15258565.001]
  • [Cites] Cancer Res. 1980 Oct;40(10):3502-7 [6108156.001]
  • [Cites] Science. 1982 Jan 8;215(4529):181-2 [6274023.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1904-9 [2450641.001]
  • [Cites] Science. 1988 Jul 15;241(4863):353-7 [2838909.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Mar;25(3):527-34 [2539297.001]
  • [Cites] Eur Respir J. 1989 May;2(5):461-9 [2547647.001]
  • [Cites] Science. 1989 Oct 27;246(4929):491-4 [2554494.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):985-91 [8094998.001]
  • [Cites] Exp Cell Res. 1994 May;212(1):36-41 [8174640.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3375-8 [7936665.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5267-74 [17545606.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6007-11 [17616654.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):665-8 [17635116.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2652-63 [17913856.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6555-60 [18006754.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):493-4 [18068625.001]
  • [Cites] Cell Biol Toxicol. 2007 Nov;23(6):367-72 [17522957.001]
  • [Cites] Mol Cancer. 2007;6:75 [18034892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 [18308936.001]
  • [Cites] Anal Biochem. 2008 Apr 15;375(2):237-48 [18211814.001]
  • [Cites] Hum Mutat. 2008 May;29(5):617-22 [18386774.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1053-9 [18304967.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3635-40 [18212743.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:1-11 [8806089.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:24-31 [8806091.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:152-9 [8806097.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):308-19 [9559342.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):766-74 [9833771.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):2931-8 [9865903.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):991-1000 [10353731.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9027-34 [15604268.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Carcinogenesis. 2005 Apr;26(4):725-31 [15677631.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1553-60 [15785753.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23):2446-8 [15944431.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):1-9 [16157194.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9601-8 [17018617.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e486 [17194187.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):85-102 [17311535.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):815-9 [17429401.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):155-8 [16397413.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1556-64 [16187286.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2116-28 [16489012.001]
  • [Cites] Differentiation. 2006 Apr;74(4):141-8 [16683984.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1927-35 [16705311.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7870-9 [16912160.001]
  • [Cites] J Cell Mol Med. 2006 Jul-Sep;10(3):588-612 [16989723.001]
  • [Cites] Oncogene. 2008 Jul 31;27(33):4615-24 [18391978.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):810-8 [18523997.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4788-97 [18408757.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14112-7 [18776048.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4226-7 [18987282.001]
  • [Cites] Mol Cancer Ther. 2008 Nov;7(11):3556-65 [19001438.001]
  • [Cites] Clin Transl Oncol. 2008 Nov;10(11):719-25 [19015068.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2009 Jan;296(1):L82-91 [18978040.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(3):791-800 [19037103.001]
  • [Cites] PLoS One. 2009;4(2):e4576 [19238210.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1795(2):92-103 [19167460.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):508-15 [19234440.001]
  • [Cites] Carcinogenesis. 2009 Apr;30(4):547-54 [19176640.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):489-500 [19477428.001]
  • [Cites] Cell. 2009 May 29;137(5):835-48 [19490893.001]
  • [Cites] Cancer Sci. 2009 Jun;100(6):1040-6 [19385971.001]
  • [Cites] PLoS One. 2009;4(7):e6146 [19582160.001]
  • (PMID = 20079948.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907-14; United States / NCI NIH HHS / CA / P50 CA070907-100003; United States / NCI NIH HHS / CA / CA070907-109001; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / U01CA084971; United States / NCI NIH HHS / CA / U01 CA084971; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-109001; United States / NCI NIH HHS / CA / CA070907-100003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 95
  • [Other-IDs] NLM/ NIHMS295304; NLM/ PMC3110769
  •  go-up   go-down


69. Hatoum OA, Binion DG, Phillips SA, O'Loughlin C, Komorowski RA, Gutterman DD, Otterson MF: Radiation induced small bowel "web" formation is associated with acquired microvascular dysfunction. Gut; 2005 Dec;54(12):1797-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These webs are likely to play a role in the pathogenesis of recurrent bowel obstruction.
  • METHODS: A 40 year old patient treated with radiation, two years previously, for an anal squamous cell cancer presented with recurrent small bowel obstruction.
  • [MeSH-minor] Adult. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Microcirculation / physiopathology. Microcirculation / radiation effects

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1986 Apr;10(2):155-70 [3705602.001]
  • [Cites] Cancer. 1975 Jun;35(6):1633-40 [1148997.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):516-26 [3384981.001]
  • [Cites] Pathol Annu. 1988;23 Pt 1:297-330 [3387138.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):865-9 [1914719.001]
  • [Cites] N Engl J Med. 1992 Sep 10;327(11):749-54 [1501650.001]
  • [Cites] Gastroenterology. 1993 Jun;104(6):1832-47 [8500743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213-36 [7713784.001]
  • [Cites] Circ Res. 1998 Sep 7;83(5):501-7 [9734472.001]
  • [Cites] Free Radic Biol Med. 1998 Nov 1;25(7):826-31 [9823548.001]
  • [Cites] AMA Arch Intern Med. 1955 Jul;96(1):26-31 [14387317.001]
  • [Cites] Trends Cardiovasc Med. 2003 Jul;13(5):201-6 [12837583.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):58-69 [12851871.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1185-9 [12714439.001]
  • [Cites] Surgery. 2004 Oct;136(4):854-60 [15467672.001]
  • [Cites] World J Surg. 1986 Apr;10(2):171-88 [3518250.001]
  • (PMID = 16127018.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774807
  •  go-up   go-down


70. Kuramoto L, Sobolev BG, Donaldson MG: On reporting results from randomized controlled trials with recurrent events. BMC Med Res Methodol; 2008;8:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On reporting results from randomized controlled trials with recurrent events.
  • Although a variety of statistical methods are available for the analysis of recurrent events, reporting the effect of an intervention on outcomes that recur is an area that remains poorly understood in clinical research.
  • The purpose of this paper is to outline guidelines for reporting results from RCTs where the outcome of interest is a recurrent event.
  • We reviewed the utility of regression models for the rate of a recurrent event by articulating the associated study questions, preenting the risk sets, and interpreting the regression coefficients.
  • RESULTS: Based on a single data set produced by simulation, we reported and contrasted results from statistical methods for evaluating treatment effect from an RCT with a recurrent outcome.
  • CONCLUSION: Our guidelines for reporting results from an RCT involving a recurrent event suggest that the study question and the objectives of the trial, such as assessing comparable groups and estimating effect size, should determine the statistical methods.
  • The guidelines should allow clinical researchers to report appropriate measures from an RCT for understanding the effect of intervention on the occurrence of a recurrent event.

  • MedlinePlus Health Information. consumer health - Falls.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1194-204 [17540006.001]
  • [Cites] BMJ. 1997 Oct 25;315(7115):1065-9 [9366737.001]
  • [Cites] Lancet. 2001 Apr 14;357(9263):1191-4 [11323066.001]
  • [Cites] Stat Methods Med Res. 2002 Apr;11(2):141-66 [12040694.001]
  • [Cites] Eur Heart J. 2003 Jan;24(1):105-12 [12559942.001]
  • [Cites] N Engl J Med. 1988 Dec 29;319(26):1701-7 [3205267.001]
  • [Cites] Lancet. 1999 Jan 9;353(9147):93-7 [10023893.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2005 Apr;60(4):530-4 [15933397.001]
  • [Cites] Stat Med. 2006 Jan 15;25(1):165-79 [16217859.001]
  • [Cites] Lifetime Data Anal. 2006 Mar;12(1):69-95 [16583300.001]
  • [Cites] Spine J. 2006 Sep-Oct;6(5):488-93 [16934716.001]
  • [Cites] Stat Med. 2006 Oct 30;25(20):3518-33 [16345026.001]
  • [Cites] Lifetime Data Anal. 2006 Dec;12(4):389-406 [17031499.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):415-9 [17452736.001]
  • [Cites] Stat Methods Med Res. 2007 Apr;16(2):103-22 [17484295.001]
  • [Cites] Pulm Pharmacol Ther. 2008;21(1):88-97 [17350868.001]
  • [Cites] JAMA. 1989 May 12;261(18):2663-8 [2709546.001]
  • [Cites] J Gerontol. 1989 Jul;44(4):M112-7 [2738307.001]
  • [Cites] Am J Epidemiol. 1993 Feb 1;137(3):342-54 [8452142.001]
  • [Cites] BMJ. 1995 Feb 18;310(6977):454-6 [7873955.001]
  • [Cites] Stat Med. 1995 Oct 15;14(19):2081-98 [8552888.001]
  • [Cites] Stat Med. 1997 Sep 30;16(18):2029-47 [9308130.001]
  • [Cites] Stat Med. 2000 Jan 15;19(1):13-33 [10623910.001]
  • (PMID = 18513418.001).
  • [ISSN] 1471-2288
  • [Journal-full-title] BMC medical research methodology
  • [ISO-abbreviation] BMC Med Res Methodol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2438437
  •  go-up   go-down


71. Michels E, Hoebeeck J, De Preter K, Schramm A, Brichard B, De Paepe A, Eggert A, Laureys G, Vandesompele J, Speleman F: CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer; 2008;8:173
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recurrent loss of part of the long arm of chromosome 11 is a well established hallmark of a subtype of aggressive neuroblastomas.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma 3.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1999 Dec 1;62(2):139-46 [10610705.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):251-7 [9324132.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):44-9 [10913676.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):680-6 [11267980.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):427-30 [11279526.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):5-10 [11464905.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):24-7 [11464895.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):531-7 [11506492.001]
  • [Cites] Anal Biochem. 2002 Apr 1;303(1):95-8 [11906156.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):605-9 [12079507.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1525-31 [12202822.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5129-33 [12234973.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):377-86 [12450793.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):122-3 [12519963.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6320-6 [14559819.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Cancer. 1998 May 15;82(10):1921-31 [9587126.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):141-52 [9739017.001]
  • [Cites] Nat Med. 1999 Mar;5(3):286-91 [10086383.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4948-57 [10490829.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9280-8 [15516980.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):e9 [15653630.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2280-99 [15800319.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):337-50 [15837623.001]
  • [Cites] Cancer Lett. 2005 Jul 8;225(1):111-20 [15922863.001]
  • [Cites] BMC Bioinformatics. 2005;6:124 [15910681.001]
  • [Cites] BMC Genomics. 2005;6:97 [16000168.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5619-28 [16044164.001]
  • [Cites] Cancer Sci. 2005 Sep;96(9):543-52 [16128739.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2243-53 [16306521.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7902-12 [16103881.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D684-8 [16381959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 9;103(19):7471-5 [16648254.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6050-62 [16778177.001]
  • [Cites] BMC Bioinformatics. 2006;7:431 [17022803.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Dec;45(12):1130-42 [16958102.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5070-8 [17075126.001]
  • [Cites] BMC Bioinformatics. 2006;7:496 [17094804.001]
  • [Cites] Genome Biol. 2006;7(9):R84 [16989664.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40330-40 [17068332.001]
  • [Cites] BMC Cancer. 2006;6:294 [17181871.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1098-108 [17823929.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):769-71 [14662434.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):294-305 [14970278.001]
  • [Cites] Am J Hum Genet. 2004 Apr;74(4):761-4 [15024693.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1599-609 [15090470.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Am J Hum Genet. 2004 Oct;75(4):727-30 [15338462.001]
  • [Cites] Cell Growth Differ. 1991 May;2(5):245-55 [1679663.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] Am J Med Genet. 1995 Jul 31;58(1):46-9 [7573155.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2483-7 [10811128.001]
  • (PMID = 18559103.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CADM1 protein, human; 0 / Cell Adhesion Molecules; 0 / Immunoglobulins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2442116
  •  go-up   go-down


72. Weiser MR, Landmann RG, Wong WD, Shia J, Guillem JG, Temple LK, Minsky BD, Cohen AM, Paty PB: Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum; 2005 Jun;48(6):1169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical salvage of recurrent rectal cancer after transanal excision.
  • PURPOSE: This study examines surgical salvage of locally recurrent rectal cancer following transanal excision of early tumors.
  • METHODS: Through retrospective review of a colorectal database we identified 50 patients who underwent attempted surgical salvage for local recurrence following initial transanal excision of T1 or T2 rectal cancer.
  • CONCLUSION: Pelvic recurrence following transanal excision of early rectal cancer is often locally advanced, requiring an extended pelvic dissection with en bloc resection of adjacent pelvic organs to achieve salvage.
  • When contemplating local excision for early rectal cancer, the risk of local recurrence, the extent and morbidity of surgery required for salvage, and the modest cure rate following salvage should be considered.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Colectomy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pelvic Exenteration. Reoperation. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793645.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Bell SW, Dehni N, Chaouat M, Lifante JC, Parc R, Tiret E: Primary rectus abdominis myocutaneous flap for repair of perineal and vaginal defects after extended abdominoperineal resection. Br J Surg; 2005 Apr;92(4):482-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Significant morbidity can result from perineal wounds, particularly after radiotherapy and extensive resection for cancer.
  • Twenty-six patients had surgery for recurrent or persistent epidermoid anal cancer or low rectal cancer, and 21 had high-dose preoperative radiotherapy.
  • [MeSH-minor] Adult. Aged. Anus Neoplasms / radiotherapy. Anus Neoplasms / surgery. Female. Humans. Length of Stay. Middle Aged. Neoplasm Recurrence, Local / surgery. Prospective Studies. Radiation Injuries / etiology. Radiotherapy / adverse effects. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Reoperation. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2005 Aug;92(8):1046 [16034808.001]
  • (PMID = 15736219.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Leblanc J, Kongkam P: Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report. Clin Med Oncol; 2009;3:59-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report.
  • A 69-year-old woman with a history of uT2 N0 post-treated anal squamous cell cancer (SCC) presented for EUS for perianal pain.
  • A sigmoidoscopy revealed mild narrowing of the anal canal and an ulcerated friable mucosa in the same area.
  • While endoscopic biopsy of suspected anal recurrences is usually sufficient, histologic or cytologic confirmation are necessary, as radiation-induced changes are difficult to differentiate from tumor recurrence.
  • This case demonstrates that EUS-FNA is useful in surveillance of anal SCC when there is a high clinical suspicion of recurrence.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1996 Jul;91(7):1309-11 [8677984.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):906-12 [10201455.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):346-50 [12594671.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):940-7 [15329901.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):535-44 [16939964.001]
  • (PMID = 20689610.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2872600
  •  go-up   go-down


75. Pasetto LM, Basso U, Sinigaglia G, Pucciarelli S, Friso ML, Rugge M, Toppan P, Agostini M, Monfardini S: Rectal cancer adjuvant chemotherapy: when is more useful? Anticancer Res; 2008 May-Jun;28(3B):1805-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal cancer adjuvant chemotherapy: when is more useful?
  • THE AIM of the study was to evaluate time-to-progression (TTP) of rectal cancer in a group of patients receiving adjuvant chemotherapy (CHT) after combined neoadjuvant treatment.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 101 consecutive rectal cancer patients who had been neoadjuvantly treated and had underne adjuvant CHT were retrospectively examined.
  • Forty-two patients had a lower (< or =5 cm from the anal verge), 54 a middle (from 6 to 10 cm) and 5 a higher (=10 cm) rectal lesion.
  • Out of locally recurrent patients, 77.8% were N+ (p=0.0026) at the pathological evaluation.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630464.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


76. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • [Transliterated title] Carcinoma ani á Islandi 1987-2003 -- lýethgrundueth rannsókn.
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • Most patients had squamous cell carcinoma (n=30).
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • Twelve patients had recurrent cancer.
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but cancer-specific survival is 82%.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-major] Anus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


77. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP, Hayden FG, Kim DH, Ing A, Campbell ER, Yu M, Fang F: Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother; 2006 Apr;50(4):1470-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Influenza is a highly infectious disease characterized by recurrent annual epidemics and unpredictable major worldwide pandemics.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Biochem. 1982 Nov 15;128(2-3):467-74 [7151789.001]
  • [Cites] Infect Immun. 1997 May;65(5):1695-700 [9125549.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Mar;42(3):640-6 [9517945.001]
  • [Cites] Infect Immun. 1998 Apr;66(4):1439-44 [9529065.001]
  • [Cites] Microbiol Immunol. 1998;42(10):697-702 [9858465.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Aug;108(8):797-805 [10453790.001]
  • [Cites] J Infect Dis. 2005 Jul 15;192(2):249-57 [15962219.001]
  • [Cites] N Engl J Med. 2005 Sep 29;353(13):1374-85 [16192482.001]
  • [Cites] Nature. 2005 Oct 20;437(7062):1108 [16228009.001]
  • [Cites] Virology. 1983 Mar;125(2):324-34 [6836915.001]
  • [Cites] Glycobiology. 1999 Dec;9(12):1313-21 [10561456.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4742-51 [10779780.001]
  • [Cites] Glycobiology. 2000 Jul;10(7):649-58 [10910970.001]
  • [Cites] Microbiol Immunol. 2000;44(6):423-30 [10941924.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Mar;45(3):743-8 [11181354.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 2001 May;129(1):29-64 [11337249.001]
  • [Cites] J Virol. 2002 Mar;76(5):2403-9 [11836418.001]
  • [Cites] J Virol. 2002 Jun;76(11):5654-66 [11991994.001]
  • [Cites] J Infect Dis. 2003 Mar 15;187(6):1000-9 [12660947.001]
  • [Cites] Clin Microbiol Rev. 2003 Apr;16(2):242-64 [12692097.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S87-97 [14730275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4620-4 [15070767.001]
  • [Cites] Clin Exp Immunol. 2004 Jul;137(1):35-40 [15196241.001]
  • [Cites] Virology. 2004 Aug 1;325(2):340-50 [15246273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10452-7 [15235128.001]
  • [Cites] Mol Cancer. 2003 Nov 5;2:38 [14613581.001]
  • [Cites] Lancet. 2004 Aug 28-Sep 3;364(9436):759-65 [15337401.001]
  • [Cites] Histochem J. 1973 May;5(3):271-90 [4593596.001]
  • [Cites] Am Rev Respir Dis. 1974 Dec;110(6):740-5 [4429269.001]
  • [Cites] Biochim Biophys Acta. 1975 Jun 12;392(2):223-32 [1169073.001]
  • [Cites] Anal Biochem. 1979 Apr 15;94(2):287-96 [464297.001]
  • [Cites] Adv Carbohydr Chem Biochem. 1982;40:131-234 [6762816.001]
  • [Cites] Infect Immun. 1983 Jul;41(1):339-44 [6305842.001]
  • [Cites] Rev Infect Dis. 1984 Mar-Apr;6 Suppl 1:S62-6 [6372039.001]
  • [Cites] Eur J Clin Microbiol. 1985 Apr;4(2):160-2 [3924604.001]
  • [Cites] Infect Immun. 1986 Feb;51(2):687-9 [3080374.001]
  • [Cites] Arch Virol. 1986;87(3-4):181-90 [3947239.001]
  • [Cites] Antiviral Res. 1986 Oct;6(6):343-53 [3022644.001]
  • [Cites] Complement. 1987;4(2):99-109 [3497774.001]
  • [Cites] J Immunol. 1988 Mar 1;140(5):1581-7 [3346542.001]
  • [Cites] Rev Infect Dis. 1988 Jan-Feb;10(1):56-75 [3281223.001]
  • [Cites] J Biol Chem. 1988 Nov 5;263(31):16316-26 [3182795.001]
  • [Cites] Science. 1989 Feb 24;243(4894 Pt 1):1074-6 [2466334.001]
  • [Cites] Infect Immun. 1989 Apr;57(4):1050-3 [2494109.001]
  • [Cites] Virology. 1989 May;170(1):346-51 [2718386.001]
  • [Cites] Biol Chem Hoppe Seyler. 1989 May;370(5):435-43 [2742753.001]
  • [Cites] J Virol Methods. 1989 Apr-May;24(1-2):27-34 [2760163.001]
  • [Cites] Infect Immun. 1990 Jul;58(7):2361-6 [2114364.001]
  • [Cites] Infect Immun. 1991 Dec;59(12):4473-7 [1682262.001]
  • [Cites] Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):906-10 [1372796.001]
  • [Cites] Curr Opin Cell Biol. 1992 Apr;4(2):257-66 [1376130.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Feb;36(2):473-6 [1605614.001]
  • [Cites] Infect Immun. 1992 Jul;60(7):2808-14 [1612746.001]
  • [Cites] Eur J Pharmacol. 1992 Sep 22;220(2-3):181-5 [1385181.001]
  • [Cites] Infect Immun. 1993 Jan;61(1):109-16 [8418033.001]
  • [Cites] Virology. 1995 Aug 1;211(1):278-84 [7645221.001]
  • [Cites] Structure. 1995 Nov 15;3(11):1197-205 [8591030.001]
  • [Cites] FASEB J. 1997 Mar;11(4):248-55 [9068613.001]
  • [CommentIn] Antimicrob Agents Chemother. 2009 Mar;53(3):1297 [19234358.001]
  • (PMID = 16569867.001).
  • [ISSN] 0066-4804
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / N01AI15435; United States / NIAID NIH HHS / AI / R43 AI056786; United States / NIAID NIH HHS / AI / N01AI30048; United States / NIAID NIH HHS / AI / N01-AI-30048; United States / NIAID NIH HHS / AI / R43AI056786; United States / NIAID NIH HHS / AI / N01-AI-15435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AREG protein, human; 0 / Amphiregulin; 0 / Antiviral Agents; 0 / Areg protein, mouse; 0 / EGF Family of Proteins; 0 / Glycoproteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Peptide Fragments; 0 / Recombinant Fusion Proteins; EC 3.2.1.18 / Neuraminidase
  • [Other-IDs] NLM/ PMC1426979
  •  go-up   go-down


78. Dackour R, Carter T, Steinberg BM: Phosphatidylinositol 3-kinase regulates early differentiation in human laryngeal keratinocytes. In Vitro Cell Dev Biol Anim; 2005 Mar-Apr;41(3-4):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection of laryngeal epithelial cells by human papillomaviruses causes recurrent respiratory papillomas, benign tumors characterized by an altered pattern of differentiation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Dec 24;274(52):37285-91 [10601294.001]
  • [Cites] EMBO J. 1996 Dec 2;15(23):6541-51 [8978681.001]
  • [Cites] J Biol Chem. 1992 Feb 5;267(4):2600-4 [1733958.001]
  • [Cites] J Biol Chem. 1996 Mar 15;271(11):6245-51 [8626417.001]
  • [Cites] J Dermatol Sci. 1998 Jul;17(3):167-81 [9697045.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 10;1584(2-3):73-80 [12385889.001]
  • [Cites] Otolaryngol Head Neck Surg. 1982 Nov-Dec;90(6):728-35 [10994421.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):910-4 [7679053.001]
  • [Cites] Biotechniques. 1993 May;14(5):752-3 [7685610.001]
  • [Cites] J Cell Sci. 1990 May;96 ( Pt 1):115-9 [2373737.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] J Virol. 2002 Feb;76(3):1533-6 [11773428.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23 ):13513-8 [9811831.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Oct;116(10):1167-71 [1698389.001]
  • [Cites] Cancer Res. 1988 Sep 1;48(17):4827-33 [3409223.001]
  • [Cites] Trends Biochem Sci. 1996 May;21(5):178-81 [8871402.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11528-35 [12547824.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):555-62 [11544023.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):8024-32 [10637513.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):968-74 [10029092.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):319-23 [12543782.001]
  • [Cites] J Gen Virol. 2002 Jul;83(Pt 7):1651-8 [12075083.001]
  • [Cites] Exp Cell Res. 2004 Apr 1;294(2):356-65 [15023526.001]
  • [Cites] Science. 1999 Apr 9;284(5412):313-6 [10195895.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):207-16 [11803464.001]
  • [Cites] J Clin Invest. 2001 Aug;108(4):527-36 [11518726.001]
  • [Cites] Anal Biochem. 1979 Jul 15;96(2):263-78 [89822.001]
  • [Cites] Cell. 1980 Apr;19(4):1033-42 [6155214.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1457-62 [10728713.001]
  • [Cites] J Cell Biol. 1981 Sep;90(3):732-7 [6895225.001]
  • [Cites] Mol Biol Cell. 2002 Aug;13(8):2946-62 [12181358.001]
  • [Cites] EMBO J. 2000 Jun 1;19(11):2393-8 [10835338.001]
  • [Cites] J Cell Physiol. 1990 Aug;144(2):326-32 [1696274.001]
  • [Cites] J Invest Dermatol. 1997 Dec;109(6):751-6 [9406816.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):303-9 [11841548.001]
  • [Cites] Cell. 1975 Nov;6(3):331-43 [1052771.001]
  • [Cites] Exp Dermatol. 2000 Jun;9(3):192-9 [10839717.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):509-13 [12080346.001]
  • [Cites] Science. 1999 Apr 9;284(5412):316-20 [10195896.001]
  • [Cites] Laryngoscope. 1987 Jun;97(6):678-85 [3035299.001]
  • [Cites] Mol Med. 2003 Mar-Apr;9(3-4):77-84 [12865943.001]
  • [Cites] FEBS Lett. 2000 Nov 10;484(3):217-23 [11078882.001]
  • [Cites] Curr Biol. 1997 Apr 1;7(4):261-9 [9094314.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):100-9 [10579915.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):40390-6 [12183446.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] J Invest Dermatol. 1983 Jul;81(1 Suppl):95s-100s [6134777.001]
  • [Cites] J Virol. 1982 Oct;44(1):393-400 [6292500.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):93-7 [12829242.001]
  • [Cites] Annu Rev Biochem. 1979;48:193-216 [382984.001]
  • (PMID = 16029072.001).
  • [ISSN] 1071-2690
  • [Journal-full-title] In vitro cellular & developmental biology. Animal
  • [ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / P50 DC00203
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Morpholines; 0 / Protein Sorting Signals; 0 / RNA, Small Interfering; 31M2U1DVID / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down


79. Egawa T, Nagashima A, Kitano M, Doi M, Hayashi S, Sekine K, Ito Y, Shimizu M, Yoshii H: [An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2053-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11].
  • An 80-year-old female visited our hospital with a chief complaint of anal pain and bleeding.
  • The patient was diagnosed by colonoscopy to have rectal cancer which invaded the perineal region.
  • As a result, this regimen was thus found to be promising for unresectable or recurrent colorectal cancer in elder patients.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219896.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


80. Lyons JG, Patel V, Roue NC, Fok SY, Soon LL, Halliday GM, Gutkind JS: Snail up-regulates proinflammatory mediators and inhibits differentiation in oral keratinocytes. Cancer Res; 2008 Jun 15;68(12):4525-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcriptional repressor Snail2 is overexpressed in head and neck squamous cell carcinomas (HNSCC) relative to nonmalignant head and neck mucosal epithelium, and in locally recurrent relative to nonrecurrent HNSCCs.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4287-95 [9336459.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Aug 28;237(3):752-7 [9299439.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1369-79 [10389921.001]
  • [Cites] J Cell Physiol. 2005 Mar;202(3):858-66 [15389643.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):127-35 [15685196.001]
  • [Cites] Development. 2005 Jul;132(14):3151-61 [15983400.001]
  • [Cites] J Allergy Clin Immunol. 2005 Nov;116(5):1144-50 [16275389.001]
  • [Cites] J Biol Chem. 2007 Dec 14;282(50):36714-23 [17940283.001]
  • [Cites] J Invest Dermatol. 2008 Feb;128(2):361-9 [17637818.001]
  • [Cites] J Cell Biol. 2002 Mar 18;156(6):1099-111 [11889141.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):901-10 [14638864.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):55-63 [14729608.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1678-84 [15014019.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4944-58 [15297395.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6511-23 [15374962.001]
  • [Cites] Anal Biochem. 1986 Dec;159(2):390-5 [3030159.001]
  • [Cites] J Virol. 1987 Oct;61(10):3004-12 [3041020.001]
  • [Cites] Int J Cancer. 1995 Mar 29;61(1):98-103 [7705939.001]
  • [Cites] J Cell Biol. 1997 Jun 16;137(6):1403-19 [9182671.001]
  • [Cites] J Biol Chem. 1998 Sep 18;273(38):24683-92 [9733767.001]
  • (PMID = 18559496.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 DE000558-16
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Chemokine CXCL1; 0 / DNA-Binding Proteins; 0 / ELF3 protein, human; 0 / Interleukin-6; 0 / Interleukin-8; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / Transcription Factors; 0 / snail family transcription factors; EC 1.13.12.- / Luciferases; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / matriptase
  • [Other-IDs] NLM/ NIHMS59581; NLM/ PMC2631428
  •  go-up   go-down


81. Cox JT: Epidemiology and natural history of HPV. J Fam Pract; 2006 Nov;Suppl:3-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-risk HPV types are now known to be necessary in the etiology of cervical cancer and to lead to both high-grade and low-grade cervical lesions.
  • They are also implicated in a substantial portion of anal, penile, and head and neck precancers and cancers.
  • HPV 16 and 18 are the most common HPV types found in cervical cancer and are responsible for approximately 70% of these cancers.
  • In contrast, low-risk HPV types, the most common of which are HPV 6 and 11, cause genital warts, low-grade cervical lesions, and recurrent respiratory papillomatosis, but they do not cause cervical or other HPV-related cancers.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366752.001).
  • [ISSN] 0094-3509
  • [Journal-full-title] The Journal of family practice
  • [ISO-abbreviation] J Fam Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


82. Chirica M, Parc Y, Tiret E, Dehni N, McNamara D, Parc R: Coloanal sleeve anastomosis (Soave procedure): the ultimate treatment option for complex rectourinary fistulas. Dis Colon Rectum; 2006 Sep;49(9):1379-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four fistulas were the result of radical prostatectomy and four followed anterior resection for rectal cancer after radiochemotherapy.
  • One patient required ileal pouch-anal anastomosis on postoperative Day 1 because of necrosis of the descended colon.
  • Two patients had recurrent fistulas at two and three months respectively.
  • One patient had moderate problems with this recurrent fistula and had his stoma closed, but the other patient required a permanent ileostomy.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Rectal Fistula / surgery. Urinary Fistula / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819570.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX: Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine; 2008 Aug 19;26 Suppl 10:K17-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The association of HPV DNA with several different ano-genital cancers other than cervical has been reported for the vulva, vagina, anus and penis.
  • In men, 80-85% of anal cancers and close to 50% of penile cancers are associated with HPV infection.
  • In women, HPV DNA is prevalent in 36-40% vulvar cancer cases and close to 90% of vaginal cancers.
  • Among HPV DNA positive ano-genital cancer cases, HPV-16 is the most frequently found followed distantly by HPV-18.
  • In benign HPV-related diseases such as genital warts or recurrent respiratory papillomatosis HPV-6 and 11, the two most frequent non-oncogenic types, are the predominant types detected.
  • We summarize the evidence linking HPV in the epidemiology and etiology of cancers of the vulva, vagina, anus and oropharynx and present recent estimates of the burden of and HPV type distribution in genital warts and in cases of HPV infection of the airways.
  • [MeSH-minor] Anus Neoplasms / virology. Female. Humans. Male. Papillomaviridae / immunology. Papillomaviridae / pathogenicity. Respiratory Tract Infections / epidemiology. Respiratory Tract Infections / virology. Uterine Cervical Diseases / epidemiology. Uterine Cervical Diseases / virology

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847554.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098803
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS73638; NLM/ PMC4366004
  •  go-up   go-down


84. Fadul CE, Kingman LS, Meyer LP, Cole BF, Eskey CJ, Rhodes CH, Roberts DW, Newton HB, Pipas JM: A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol; 2008 Nov;90(2):229-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the combination of thalidomide and irinotecan, we conducted a phase II trial in adults with newly-diagnosed or recurrent GBM.
  • The intention to treat group with recurrent disease included 16 patients who had a 6-month PFS of 19% (95% CI: 4-46%) and with newly-diagnosed disease included 10 patients who had a 6-month PFS of 40% (95% CI: 12-74%).

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Aug 12;356(9229):566-7 [10950238.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] J Neurooncol. 2001 Jan;51(1):41-5 [11349879.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4 Suppl 3):23-6 [12014864.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6621-8 [14528287.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1745-8 [14534892.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):365-75 [15015670.001]
  • [Cites] Neurology. 2004 Aug 10;63(3):535-7 [15304589.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):417-23 [9054955.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2044-6 [15470485.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):295-301 [15864130.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 25;821(2):221-8 [15936253.001]
  • [Cites] J Pharm Biomed Anal. 2005 Sep 1;39(1-2):299-304 [16085147.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1549-51 [16350272.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1568-74 [16342649.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2079-80 [16687729.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2079-80 [16696148.001]
  • [Cites] Am J Hematol. 2006 Jun;81(6):420-2 [16680743.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1883-90 [16986123.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Sep;4(9):658-9 [17099621.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2339-43 [17107907.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):216-22 [18314417.001]
  • [Cites] J Neurooncol. 2008 Aug;89(1):113-8 [18438609.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Treat Rev. 2000 Oct;26(5):351-62 [11006136.001]
  • (PMID = 18661102.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023108
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS539769; NLM/ PMC3885231
  •  go-up   go-down


85. Baysal BE: A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS One; 2007 May 09;2(5):e436
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia.
  • CONCLUSIONS: The identification of a recurrent, inactivating stop-codon mutation in the SDHB gene in normal blood cells suggests that SDHB is targeted by a cytidine deaminase enzyme.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Oct 15;104(8):2224-34 [15231578.001]
  • [Cites] Hum Genet. 2003 Aug;113(3):228-37 [12811540.001]
  • [Cites] Eur J Haematol. 1999 Sep;63(3):180-91 [10485273.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10933-40 [15572694.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] BMC Med Genet. 2005;6:39 [16288654.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):415-25 [16723977.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7615-20 [16885361.001]
  • [Cites] Anal Biochem. 2007 Jan 1;360(1):84-91 [17107651.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):7-10 [17190841.001]
  • [Cites] BMC Biol. 2007;5:12 [17376234.001]
  • [Cites] J Appl Physiol (1985). 2005 Feb;98(2):715-21 [15649883.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Nat Genet. 2000 Aug;25(4):375-6 [10932175.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):38-50 [11727199.001]
  • [Cites] Annu Rev Immunol. 2002;20:165-96 [11861601.001]
  • [Cites] J Med Genet. 2002 Mar;39(3):178-83 [11897817.001]
  • [Cites] Trends Genet. 2003 Apr;19(4):207-16 [12683974.001]
  • [Cites] Annu Rev Genet. 1990;24:305-26 [2088171.001]
  • (PMID = 17487275.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA11236
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Terminator; 0 / DNA Primers; 0 / RNA, Messenger; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Other-IDs] NLM/ PMC1855983
  • [General-notes] NLM/ Original DateCompleted: 20070727
  •  go-up   go-down


86. Gericke B, Raila J, Sehouli J, Haebel S, Könsgen D, Mustea A, Schweigert FJ: Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer; 2005;5:133
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients.
  • A truncated form of TTR has recently been described to be part of a set of biomarkers for the diagnosis of ovarian cancer.
  • The main aim of the study was therefore to characterize differences in microheterogeneity between ascitic fluid and plasma of women affected with ovarian cancer and to evaluate the tumor site as the possible source of TTR.
  • METHODS: Subjects were 48 women with primary invasive epithelial ovarian cancer or recurrent ovarian carcinoma.
  • CONCLUSION: The severity of the cancer associated catabolism as well as the inflammation status affect serum TTR and RBP levels.
  • [MeSH-minor] Adult. Aged. C-Reactive Protein / biosynthesis. Carcinoma / blood. Carcinoma / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Inflammation. Middle Aged. Peroxidases / metabolism. Recurrence. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Obstet Gynecol. 2000 Feb;12(1):39-42 [10752515.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 May;4(1):7-15 [15975260.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 3:141-4 [11079131.001]
  • [Cites] Arch Intern Med. 2001 Dec 10-24;161(22):2733-7 [11732940.001]
  • [Cites] Anal Biochem. 2002 Feb 1;301(1):49-56 [11811966.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Muscle Nerve. 2002 Sep;26(3):417-20 [12210373.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1281-91 [12553432.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1320-4 [12553437.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1344-8 [12553442.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):191-7 [12716133.001]
  • [Cites] Hum Reprod. 2003 Jun;18(6):1259-64 [12773456.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 10;310(1):242-6 [14511677.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49707-13 [14507924.001]
  • [Cites] Nutr Cancer. 2003;46(2):148-57 [14690790.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):337-45 [14695346.001]
  • [Cites] Int J Vitam Nutr Res. 2003 Nov;73(6):423-30 [14743546.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1223-9 [15154651.001]
  • [Cites] J Obstet Gynaecol Can. 2004 Aug;26(8):717-28 [15307976.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Zentralbl Gynakol. 2004 Oct;126(5):315-22 [15478050.001]
  • [Cites] Ann Nutr Metab. 2004;48(4):241-5 [15331882.001]
  • [Cites] Curr Oncol Rep. 2004 Nov;6(6):456-62 [15485615.001]
  • [Cites] J Clin Pathol. 1991 Jul;44(7):573-5 [1713221.001]
  • [Cites] Sci China B. 1991 Nov;34(11):1312-8 [1666289.001]
  • [Cites] Gynecol Obstet Invest. 1994;37(2):135-40 [8150370.001]
  • [Cites] Nutr Rev. 1994 Feb;52(2 Pt 2):S13-23 [8202278.001]
  • [Cites] Annu Rev Nutr. 1994;14:495-533 [7946531.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11 Suppl):135-9 [8608044.001]
  • [Cites] Neurosci Lett. 1997 Dec 5;238(3):123-6 [9464635.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):26-30 [9705825.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Gen Comp Endocrinol. 2000 Sep;119(3):241-55 [11017772.001]
  • (PMID = 16225703.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Prealbumin; 9007-41-4 / C-Reactive Protein; EC 1.11.1.- / Peroxidases
  • [Other-IDs] NLM/ PMC1274304
  •  go-up   go-down


87. Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter TE: Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol; 2008 Jun;31(3):264-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
  • OBJECTIVES: A prospective phase II trial was conducted to evaluate the feasibility, safety, and pathologic response rate of preoperative capecitabine and accelerated synchronous integrated boost (SIB) intensity-modulated radiotherapy (IMRT) in patients with locally advanced rectal cancer.
  • At a median follow-up of 26 months (range, 15-40), all patients were alive without evidence of recurrent disease.
  • Of 3 patients who had tumors within 5 cm of the anal verge, 2 underwent sphincter-sparing procedures.
  • CONCLUSIONS: Preoperative chemoradiation with capecitabine and SIB-IMRT is well tolerated and results in an encouraging pCR rate for patients with locally advanced rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525306.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Sandiford N, Prussia PR, Chiappa A, Zbar AP: Synchronous mucinous adenocarcinoma of the rectosigmoid seeding onto a pre-existing anal fistula. Int Semin Surg Oncol; 2006;3:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous mucinous adenocarcinoma of the rectosigmoid seeding onto a pre-existing anal fistula.
  • Carcinoma within a long-standing fistula-in-ano is rare and may be defined by specific neoplastic involvement of the fistulous track in the absence of rectal mucosal carcinoma.
  • The presence of a carcinoma of mucinous histology occurring synchronously in the perianal region and the colon is exceptionally rare.
  • Subsequent clinical follow-up and CT examination of the patient has not revealed recurrent disease at 14 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Mar;39(3):1295-9 [199346.001]
  • [Cites] J R Soc Med. 1992 Jun;85(6):361 [1625275.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):544-5; author reply 545 [14994107.001]
  • [Cites] Aust N Z J Surg. 1965 Feb;34:178-87 [14271060.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):835-6 [12794588.001]
  • [Cites] Chirurg. 2001 May;72(5):573-7 [11383070.001]
  • [Cites] South Med J. 1979 Jun;72(6):764-6 [221988.001]
  • [Cites] Postgrad Med J. 1987 Jun;63(740):503-4 [2829151.001]
  • [Cites] Am J Clin Pathol. 1988 Jun;89(6):809-12 [2835897.001]
  • [Cites] Am J Gastroenterol. 1988 Apr;83(4):460-2 [3348199.001]
  • [Cites] Dis Colon Rectum. 1988 Jan;31(1):68-70 [3366030.001]
  • [Cites] J R Soc Med. 1988 Apr;81(4):217-9 [3373467.001]
  • [Cites] Postgrad Med J. 1987 Mar;63(737):213-4 [3671263.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):602 [4027530.001]
  • [Cites] Am J Proctol. 1970 Apr;21(2):103-12 [4330480.001]
  • [Cites] Rev Esp Enferm Dig. 1995 Apr;87(4):342-3 [7794647.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1050-2 [7648150.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):664-5 [6478153.001]
  • [Cites] JAMA. 1970 Sep 21;213(12):2083 [5468765.001]
  • [Cites] Dis Colon Rectum. 1981 Oct;24(7):562-6 [6271516.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • (PMID = 16961916.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1592294
  •  go-up   go-down


89. Mariani P, Ghanneme A, De la Rochefordière A, Girodet J, Falcou MC, Salmon RJ: Abdominoperineal resection for anal cancer. Dis Colon Rectum; 2008 Oct;51(10):1495-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominoperineal resection for anal cancer.
  • PURPOSE: Following initial radiotherapy or chemoradiotherapy for the treatment of anal cancer, patients who present with either persistent or locally recurrent disease are treated by abdominoperineal resection.
  • METHODS: Over a 34-year period (1969-2003), 422 patients with nonmetastatic anal cancer were treated with a curative intent.
  • RESULTS: Forty-one patients underwent abdominoperineal resection for persistent disease and 42 for locally recurrent disease.
  • Surgery, whether for persistent or locally recurrent disease, did not affect the 5-year survival rate.
  • CONCLUSIONS: Abdominoperineal resection for nonmetastatic anal cancer is associated with a high morbidity rate but may result in long-term survival regardless of the indication.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Perineum / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521675.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Lenz EM, Spear M, Drake C, Pollard CR, Ward M, Schulz-Utermoehl T, Harrison M: Characterisation and identification of the human N+-glucuronide metabolite of cediranib. J Pharm Biomed Anal; 2010 Nov 2;53(3):526-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cediranib (4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline; RECENTIN), a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) of all three VEGF receptors, is currently in Phase III clinical trials for the first-line treatment of colorectal cancer and the treatment of recurrent glioblastoma.
  • During its clinical development a unique human metabolite, an N(+)-glucuronide, was identified as a major circulating metabolite and one of the major metabolites excreted into faeces.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20409669.001).
  • [ISSN] 1873-264X
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucuronides; 0 / Quinazolines; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; NQU9IPY4K9 / cediranib
  •  go-up   go-down


91. Liu J, Ranka S, Kahveci T: Classification and feature selection algorithms for multi-class CGH data. Bioinformatics; 2008 Jul 1;24(13):i86-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent chromosomal alterations provide cytological and molecular positions for the diagnosis and prognosis of cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2001;17 Suppl 1:S157-64 [11473005.001]
  • [Cites] Neural Comput. 2007 May;19(5):1155-78 [17381263.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Anal Cell Pathol. 2001;23(1):29-37 [11790857.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2429-37 [15087314.001]
  • [Cites] Science. 1972 Jun 23;176(4041):1340-1 [4338345.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Mol Carcinog. 1993;7(3):139-46 [8489711.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:645-52 [7587125.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1437-44 [8695864.001]
  • [Cites] J Comput Biol. 1999 Spring;6(1):37-51 [10223663.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):327-41 [15645488.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2280-99 [15800319.001]
  • [Cites] BMC Bioinformatics. 2005;6:67 [15784140.001]
  • [Cites] J Bioinform Comput Biol. 2005 Apr;3(2):185-205 [15852500.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • [Cites] IEEE Trans Nanobioscience. 2005 Sep;4(3):228-34 [16220686.001]
  • [Cites] Biotechniques. 2006 Mar;40(3):269-70, 272 [16568815.001]
  • [Cites] BMC Bioinformatics. 2006;7:197 [16606446.001]
  • [Cites] Bioinformatics. 2006 Aug 15;22(16):1971-8 [16705014.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1228-9 [11751233.001]
  • (PMID = 18586749.001).
  • [ISSN] 1367-4811
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2718623
  •  go-up   go-down


92. Schertl S, Hartmann RW, Batzl-Hartmann C, Spruss T, Maucher A, von Angerer E, Schiller CD, Schneider MR, Gust R, Schönenberger H: Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies. J Cancer Res Clin Oncol; 2007 Mar;133(3):153-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.
  • It is assumed that such compounds are more efficient than the established endocrine therapeutic measures and can affect the development of hormone refractory prostate cancer (PC).
  • Therefore, the contribution of an additional mechanism to the anti-prostate cancer activity of meso-4-PtLL', presumably owing to its estrogenic potency, must be considered.
  • This assumption was supported by test results with diethylstilbestrol (DES) (non-steroidal estrogen) on the Dunning R3327 PC of the rat relapsed after orchiectomy.
  • This tumor model was strongly inhibited by DES.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 1992;118(5):339-43 [1583065.001]
  • [Cites] J Steroid Biochem Mol Biol. 1996 May;58(2):243-8 [8809207.001]
  • [Cites] Cancer. 1990 Sep 1;66(5 Suppl):1045-57 [2144206.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jul;23(7):1005-15 [3665986.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1998 Jul;89(7):657-64 [9739587.001]
  • [Cites] Arch Pharm (Weinheim). 1993 Jul;326(7):405-13 [8357303.001]
  • [Cites] J Cancer Res Clin Oncol. 1991;117(1):33-6 [1997466.001]
  • [Cites] Urology. 1999 Dec;54(6A Suppl):19-21 [10606280.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(1):35-43 [1309532.001]
  • [Cites] Can J Physiol Pharmacol. 1971 Jun;49(6):554-8 [4932541.001]
  • [Cites] Prostate. 1984;5(1):1-17 [6694914.001]
  • [Cites] J Steroid Biochem Mol Biol. 1991;40(1-3):207-14 [1958522.001]
  • [Cites] J Nutr. 2002 Dec;132(12):3623-31 [12468598.001]
  • [Cites] Urology. 2003 Dec 29;62 Suppl 1:87-94 [14747046.001]
  • [Cites] Prostate. 1999 Jul 1;40(2):76-82 [10386467.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(12):707-16 [8408183.001]
  • [Cites] Arch Pharm (Weinheim). 2004 Dec;337(12):654-67 [15597399.001]
  • [Cites] Urology. 2000 Mar;55(3):328-33 [10699602.001]
  • [Cites] Urology. 2002 Sep;60(3 Suppl 1):94-100; discussion 100 [12231060.001]
  • [Cites] Prostate. 2000 Jun 1;43(4):295-302 [10861749.001]
  • [Cites] Cancer Lett. 1979 Jan;6(1):45-50 [544011.001]
  • [Cites] Prostate. 1989;15(2):135-48 [2798231.001]
  • [Cites] Arch Pharm (Weinheim). 2004 Jun;337(6):335-48 [15188223.001]
  • [Cites] World J Urol. 2003 May;21(1):31-6 [12756492.001]
  • [Cites] J Cancer Res Clin Oncol. 1986;112(3):258-65 [2946698.001]
  • [Cites] J Urol. 1977 Jul;118(1 Pt 2):216-20 [875219.001]
  • [Cites] Eur Urol. 2004 Feb;45(2):245-51; discussion 251 [14734014.001]
  • [Cites] Anal Biochem. 1988 Jun;171(2):225-37 [3044184.001]
  • [Cites] Cancer Res. 1978 Nov;38(11 Pt 2):4353-9 [698976.001]
  • [Cites] J Cancer Res Clin Oncol. 1980;97(2):167-86 [7462296.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1648-53 [9811314.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):491-503 [14755680.001]
  • [Cites] Cancer Treat Rep. 1977 Mar-Apr;61(2):273-87 [872132.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(4):566-74 [9274436.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] Arch Pharm (Weinheim). 2004 Jun;337(6):349-59 [15188224.001]
  • [Cites] Am J Clin Oncol. 1999 Oct;22(5):471-4 [10521061.001]
  • [Cites] Anal Biochem. 1990 Jun;187(2):262-7 [2382827.001]
  • [Cites] Urology. 1998 Aug;52(2):257-60 [9697791.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1003-7 [11948106.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(5):334-8 [1583064.001]
  • (PMID = 17024493.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / (1,2-bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine)platinum(II); 0 / (1,2-bis(2,6-difluoro-4-hydroxyphenyl)ethylenediamine)sulfatoplatinum(II); 0 / 2,6-dimethyldifuro-8-pyrone; 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Furans; 0 / Organoplatinum Compounds; 0 / Pyrones; 117773-99-6 / (1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum (II); 3XMK78S47O / Testosterone; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


93. Agar NY, Malcolm JG, Mohan V, Yang HW, Johnson MD, Tannenbaum A, Agar JN, Black PM: Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal Chem; 2010 Apr 1;82(7):2621-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five recurrent and progressive meningiomas for which surgical specimens were available from the original and progressed grades were selected and tested against nonprogressive high-grade meningiomas, high-grade gliomas, and nontumor brain specimens.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18126-31 [18776051.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):981-7 [14871976.001]
  • [Cites] Anal Chem. 2004 Feb 15;76(4):1145-55 [14961749.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):245-52 [15113100.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1057-68 [15466373.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] J Am Soc Mass Spectrom. 1999 Jan;10(1):67-71 [9888186.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9093-100 [15604278.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):394-401 [15677390.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1720-6 [16546995.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Anal Chem. 2007 Oct 1;79(19):7416-23 [17822313.001]
  • [Cites] J Cell Mol Med. 2008 Sep-Oct;12(5A):1535-47 [18266982.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • (PMID = 20196536.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIBIB NIH HHS / EB / U54 EB005149-030003; United States / NIBIB NIH HHS / EB / U54 EB005149; United States / NCRR NIH HHS / RR / P41 RR-13218; United States / NCRR NIH HHS / RR / RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NIBIB NIH HHS / EB / EB005149-030003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS184740; NLM/ PMC2852177
  •  go-up   go-down


94. Kim C, Layman S, Morré DM, Morré DJ: Structural changes revealed by Fourier transform infrared and circular dichroism spectroscopic analyses underlie tNOX periodic oscillations. Dose Response; 2005;3(3):391-413
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taken together the findings suggest that the regular patterns of oscillations exhibited by the ECTO-NOX proteins are accompanied by recurrent global changes in the conformation of the protein backbone that directly modulate enzymatic activity.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1995 Nov 22;1240(1):11-7 [7495842.001]
  • [Cites] Biochim Biophys Acta. 1995 Dec 13;1240(2):201-8 [8541291.001]
  • [Cites] Biochemistry. 1994 Aug 23;33(33):10022-5 [8060970.001]
  • [Cites] Anal Biochem. 1993 Feb 15;209(1):32-44 [8465960.001]
  • [Cites] Biochem J. 1992 Jun 15;284 ( Pt 3):625-8 [1622384.001]
  • [Cites] Protein Eng. 1992 Apr;5(3):191-5 [1409538.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Aug 31;147(1):506-12 [3632681.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Jul;70(7):2037-41 [4516204.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Nov;71(11):4389-91 [4530989.001]
  • [Cites] Biol Bull. 1972 Dec;143(3):513-24 [4666989.001]
  • [Cites] Science. 1968 May 31;160(3831):1011-4 [5647846.001]
  • [Cites] Free Radic Res. 2003 Aug;37(8):795-808 [14567438.001]
  • [Cites] J Photochem Photobiol B. 2003 Apr;70(1):7-12 [12745241.001]
  • [Cites] Int J Plant Sci. 2002 Jul;163(4):543-7 [12448422.001]
  • [Cites] Biochemistry. 2002 Oct 8;41(40):11941-5 [12356293.001]
  • [Cites] Biochim Biophys Acta. 2002 Feb 10;1559(1):10-20 [11825584.001]
  • [Cites] Biochemistry. 2002 Mar 19;41(11):3732-41 [11888291.001]
  • [Cites] Biochim Biophys Acta. 2002 Jan 31;1594(1):74-83 [11825610.001]
  • [Cites] Biochim Biophys Acta. 2001 Jun 20;1539(3):192-204 [11420117.001]
  • [Cites] Trends Biochem Sci. 2000 Oct;25(10):459-61 [11050424.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 20;1498(1):44-51 [11042349.001]
  • [Cites] Biochim Biophys Acta. 1999 May 26;1412(1):66-77 [10354495.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):446-52 [9417102.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11221-7 [9111023.001]
  • [Cites] Arch Biochem Biophys. 1997 Jun 1;342(1):38-47 [9185612.001]
  • [Cites] Annu Rev Genet. 1996;30:579-601 [8982466.001]
  • [Cites] Eur J Cancer. 1996 Oct;32A(11):1995-2003 [8943687.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1831-5 [7892186.001]
  • (PMID = 18648622.001).
  • [ISSN] 1559-3258
  • [Journal-full-title] Dose-response : a publication of International Hormesis Society
  • [ISO-abbreviation] Dose Response
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2475952
  •  go-up   go-down


95. Burrow AA, Marullo A, Holder LR, Wang YH: Secondary structure formation and DNA instability at fragile site FRA16B. Nucleic Acids Res; 2010 May;38(9):2865-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They often are found in genes involved in tumorigenesis and map to over half of all known cancer-specific recurrent translocation breakpoints.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Genet. 1984;67(2):136-42 [6430783.001]
  • [Cites] J Biol Chem. 1996 Oct 4;271(40):24325-8 [8798682.001]
  • [Cites] Am J Hum Genet. 1988 Sep;43(3):265-73 [3137811.001]
  • [Cites] Science. 1991 Jun 21;252(5013):1711-4 [1675488.001]
  • [Cites] Genet Anal Tech Appl. 1991 Sep;8(6):161-6 [1721827.001]
  • [Cites] Biochemistry. 1993 Aug 24;32(33):8568-74 [8395209.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4950-4 [8197163.001]
  • [Cites] Biochemistry. 1994 Nov 29;33(47):14185-96 [7947830.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1571-80 [7729431.001]
  • [Cites] Cell. 1995 May 19;81(4):533-40 [7758107.001]
  • [Cites] Nucleic Acids Res. 1995 Oct 25;23(20):4202-9 [7479085.001]
  • [Cites] Biochemistry. 1996 Apr 16;35(15):5041-53 [8664297.001]
  • [Cites] J Biol Chem. 1996 Sep 20;271(38):22937-40 [8798475.001]
  • [Cites] J Mol Biol. 1996 Nov 8;263(4):511-6 [8918933.001]
  • [Cites] Cell. 1997 Feb 7;88(3):367-74 [9039263.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4587-92 [9114034.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):16798-806 [9201985.001]
  • [Cites] Nat Genet. 1997 Nov;17(3):298-304 [9354793.001]
  • [Cites] Hum Mol Genet. 1998 Apr;7(4):755-61 [9499431.001]
  • [Cites] Trends Genet. 1998 Dec;14(12):501-6 [9865156.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 1;27(21):4235-40 [10518616.001]
  • [Cites] Am J Hum Genet. 2005 Feb;76(2):302-11 [15625623.001]
  • [Cites] Genes Dev. 2005 Nov 15;19(22):2715-26 [16291645.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(12):4420-7 [10825205.001]
  • [Cites] Chromosome Res. 2000;8(8):677-88 [11196131.001]
  • [Cites] Nature. 2001 Aug 2;412(6846):553-7 [11484057.001]
  • [Cites] Nature. 2001 Aug 2;412(6846):557-61 [11484058.001]
  • [Cites] Genes Dev. 2001 Sep 1;15(17):2177-96 [11544175.001]
  • [Cites] Nat Genet. 2002 May;31(1):37-46 [11967533.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):17315-9 [11880377.001]
  • [Cites] Cell. 2002 Dec 13;111(6):779-89 [12526805.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3406-15 [12824337.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(20):7143-51 [14517285.001]
  • [Cites] Cytogenet Genome Res. 2003;100(1-4):85-8 [14526167.001]
  • [Cites] J Mol Biol. 2004 Feb 20;336(3):639-54 [15095978.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6701-9 [15254237.001]
  • [Cites] Am J Hum Genet. 2004 Oct;75(4):654-60 [15309689.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):41715-26 [15292165.001]
  • [Cites] J Mol Biol. 1967 Jun 14;26(2):365-9 [4291934.001]
  • [Cites] Annu Rev Biophys Bioeng. 1978;7:19-35 [78683.001]
  • [Cites] Cytogenet Cell Genet. 1980;28(1-2):87-94 [7449440.001]
  • [Cites] Cell. 1982 Apr;28(4):767-79 [6178514.001]
  • [Cites] Am J Hum Genet. 1984 Jan;36(1):110-22 [6198907.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):42568-72 [16204246.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):70-8 [16229940.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):4-12 [16229941.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4381-8 [16732333.001]
  • [Cites] Nucleic Acids Res. 2006;34(20):6044-50 [17071963.001]
  • [Cites] Nucleic Acids Res. 2006;34(21):6352-61 [17142224.001]
  • [Cites] Mol Cell. 2007 Aug 3;27(3):367-79 [17679088.001]
  • [Cites] Cytogenet Genome Res. 2007;118(2-4):260-9 [18000379.001]
  • [Cites] Annu Rev Genet. 2007;41:169-92 [17608616.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27 [18594563.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Oct;47(10):860-72 [18615677.001]
  • [Cites] Cytogenet Genome Res. 2008;121(3-4):196-200 [18758159.001]
  • [Cites] Nat Struct Mol Biol. 2009 Feb;16(2):159-67 [19136956.001]
  • [Cites] BMC Genomics. 2009;10:59 [19183484.001]
  • [Cites] Am J Hum Genet. 1987 Nov;41(5):882-90 [3674017.001]
  • (PMID = 20071743.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085826; United States / NCI NIH HHS / CA / CA113863; United States / NCI NIH HHS / CA / CA85826
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 2.7.7.7 / DNA-Directed DNA Polymerase
  • [Other-IDs] NLM/ PMC2875025
  •  go-up   go-down


96. Ribeiro MJ, Idbaih A, Thomas C, Remy P, Martin-Duverneuil N, Samson Y, Donadieu J, Hoang-Xuan K: 18F-FDG PET in neurodegenerative Langerhans cell histiocytosis : results and potential interest for an early diagnosis of the disease. J Neurol; 2008 Apr;255(4):575-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: ND-LCH patients demonstrated recurrent abnormalities including bilateral hypometabolism in the cerebellum, the basal ganglia (caudate nuclei), frontal cortex and, bilateral, a relatively increased metabolism in the amygdalae (p < 0.001).
  • CONCLUSIONS: ND-LCH demonstrates a recurrent 18F-FDG PET metabolic signature.

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • MedlinePlus Health Information. consumer health - Degenerative Nerve Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pediatr Hematol Oncol. 1993 May;15(2):245-54 [8498649.001]
  • [Cites] J Pediatr. 2004 Mar;144(3):344-50 [15001940.001]
  • [Cites] Arch Dis Child. 1996 Jul;75(1):17-24 [8813865.001]
  • [Cites] Brain Dev. 1991 May;13(3):193-5 [1928614.001]
  • [Cites] Med Image Anal. 1996 Mar;1(1):35-51 [9873920.001]
  • [Cites] J Neurol Sci. 1996 Dec;144(1-2):77-83 [8994107.001]
  • [Cites] Ann Neurol. 1988 Sep;24(3):399-406 [3265862.001]
  • [Cites] Arch Dis Child. 2002 Feb;86(2):130-1 [11827909.001]
  • [Cites] Brain. 2005 Apr;128(Pt 4):829-38 [15705614.001]
  • [Cites] Med Pediatr Oncol. 1999 Nov;33(5):486-92 [10531574.001]
  • [Cites] Pediatr Blood Cancer. 2005 Mar;44(3):286-8 [15481071.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):880-91 [15140741.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):2074-82 [16625352.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1348 [12933957.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2961-7 [12885816.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Aug;22(8):986-1004 [12906253.001]
  • [Cites] J Child Neurol. 2000 Mar;15(3):150-6 [10757469.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Nov;15(10):1921-8 [7863943.001]
  • [Cites] J Pediatr. 2002 Sep;141(3):435-40 [12219070.001]
  • [Cites] Hematol Oncol Clin North Am. 1998 Apr;12 (2):287-305 [9561901.001]
  • [Cites] Arch Neurol. 1989 Sep;46(9):1001-3 [2775003.001]
  • (PMID = 18227990.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


97. Tokar M, Bobilev D, Zalmanov S, Geffen DB, Walfisch S: Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie; 2006 Feb;29(1-2):30-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature.
  • BACKGROUND: We report on a patient with squamous cell anal carcinoma and liver metastases, who underwent multimodal treatment for cure, consisting of repeated partial hepatectomy in combination with chemoradiotherapy.
  • PATIENTS AND METHODS: A 54-year-old woman presented with squamous cell anal carcinoma and liver metastases.
  • 2 and 5 years after presentation, the patient underwent repeated partial hepatectomies for recurrent liver disease.
  • RESULTS: Repeated partial hepatectomy led to prolonged survival in a patient with squamous cell anal carcinoma metastatic to the liver.
  • CONCLUSIONS: This is the first report of aggressive partial hepatectomy for recurrent liver metastases resulting from anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • (PMID = 16514253.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


98. Mureşan M, Bancu S, Bara T, Bancu L, Turcu M, Mureşan S: [Local recurrence after the sphincter-saving operations and abdominal perineal resection in rectal cancer]. Chirurgia (Bucur); 2009 Jul-Aug;104(4):415-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrence after the sphincter-saving operations and abdominal perineal resection in rectal cancer].
  • By local recurrence we define the appearance of the same anatomopathological type of cancer like the one initially described in the primary tumor, limited at the rectum or pelvis.The study is based on the analysis of all the cases with rectal cancer who undergone surgical procedures in Surgical Clinic No.2 Tg.
  • Using the most important parameters for each patient we identified some risk factors for the recurrence of the rectal cancer: surgical procedures--there were no major variations in the local recurrence between the sphincter-saving operations and abdominal perineal resections.
  • The recurrent rectal cancer is more frequent in aged patients with high aggressive adenocarcinomas.
  • [MeSH-major] Abdomen / surgery. Adenocarcinoma / surgery. Anal Canal. Neoplasm Recurrence, Local / surgery. Perineum / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / surgery. Aged. Carcinoma, Squamous Cell / surgery. Digestive System Surgical Procedures / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886048.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


99. Lee J, Corman M: Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature. J Gastrointest Surg; 2009 Jan;13(1):150-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature.
  • INTRODUCTION: Tumors arising from the anal canal are rare, comprising 1.5% of all gastrointestinal tumors in the USA.
  • The vast majority of these anal cancers are epidermoid (cloacogenic/basaloid and squamous cell carcinomas), while adenocarcinomas reportedly occur 5% to 19% of the time.
  • Because of its rarity, reports about anal adenocarcinoma are limited to small retrospective studies and case reports.
  • Moreover, no series has directly compared outcomes between patients undergoing the various available treatment options, making it difficult to determine the optimal treatment for this aggressive cancer.
  • Current management of this cancer remains controversial, with some authors believing abdominoperineal resection with permanent colostomy should be considered the standard treatment.
  • CASE PRESENTATION: We describe a case of recurrent anal adenocarcinoma after conservative management with local excision and adjuvant chemoradiation therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Agents / therapeutic use. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Colectomy / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1996 Dec;49(12):1009-11 [9038740.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):669-78 [12573754.001]
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Sep;9(5):402-4 [17043960.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):233-7 [7840386.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1320-4 [14530668.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Semin Surg Oncol. 1994 May-Jun;10(3):235-40 [8085101.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1199-205 [10613313.001]
  • [Cites] Histopathology. 1994 Dec;25(6):507-16 [7698728.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):58-61 [1850518.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):805-15 [9264365.001]
  • (PMID = 18810561.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


100. Brunner A, Schönhuber G, Waldner M, Schaefer G, Mikuz G, Verdorfer I: Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system. Anal Quant Cytol Histol; 2008 Oct;30(5):297-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system.
  • OBJECTIVE: To evaluate differences in chromosomal aberrations in recurrent urothelial cancer (UC) of the bladder between the World Health Organization (WHO) 1973 and 2004 classification a retrospective study was performed.
  • STUDY DESIGN: Primary and recurrent UCs of the bladder of 22 patients diagnosed at the Institute of Pathology, Medical University of Innsbruck were analyzed by comparative genomic hybridization, fluorescence in situ hybridization and immunohistochemistry (Ki-67, p53).

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980162.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement